258 related articles for article (PubMed ID: 27860480)
1. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
[TBL] [Abstract][Full Text] [Related]
2. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation testing in melanoma: results from a German observational multicenter study.
Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
[TBL] [Abstract][Full Text] [Related]
4. The T1799A point mutation is present in posterior uveal melanoma.
Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutations are detectable in conjunctival but not uveal melanomas.
Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
[TBL] [Abstract][Full Text] [Related]
7. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
[TBL] [Abstract][Full Text] [Related]
8. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
[TBL] [Abstract][Full Text] [Related]
9. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
10. One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma.
Furdova A; Strmen P; Waczulikova I; Chorvath M; Sramka M; Slezak P
Eur J Ophthalmol; 2012; 22(2):226-35. PubMed ID: 21534252
[TBL] [Abstract][Full Text] [Related]
11. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
[TBL] [Abstract][Full Text] [Related]
12. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
13. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
14. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunohistochemical analyses of uveal melanoma patient cohort.
Sarubi HC; Pereira NB; Gomes CC; Gomez RS; Carmo ACM; Melo FM; Bastos-Rodrigues L; Pedrosa MS; Friedman E; De Marco L
Melanoma Res; 2019 Jun; 29(3):248-253. PubMed ID: 30480620
[TBL] [Abstract][Full Text] [Related]
16. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
17. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
20. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
